KRMD Repro Med Systems Inc
Price (delayed)
$2.85
Market cap
$130.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$126.07M
Repro Med Systems, Inc. dba KORU Medical System develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM
Highlights
The gross profit is up by 22% year-on-year and by 4.4% since the previous quarter
The revenue has grown by 12% YoY and by 3.8% from the previous quarter
KRMD's debt is down by 8% year-on-year but it is up by 7% since the previous quarter
KRMD's EPS is down by 47% year-on-year
The net income has declined by 45% year-on-year
Key stats
What are the main financial stats of KRMD
Market
Valuations
Earnings
Shares outstanding
45.84M
Market cap
$130.64M
Enterprise value
$126.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.37
Price to sales (P/S)
4.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.94
Revenue
$31.99M
Gross profit
$20.1M
Operating income
-$7.05M
Net income
-$11.97M
EBIT
-$6.53M
EBITDA
-$5.62M
Free cash flow
-$1.7M
Per share
Balance sheet
Liquidity
EPS
-$0.25
EPS diluted
-$0.25
Free cash flow per share
-$0.04
Book value per share
$0.39
Revenue per share
$0.7
TBVPS
$0.58
Total assets
$27.39M
Total liabilities
$9.66M
Debt
$4.24M
Equity
$17.73M
Working capital
$12.6M
Debt to equity
0.24
Current ratio
2.99
Quick ratio
2.22
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-17.6%
Gross margin
62.8%
Net margin
-37.4%
Operating margin
-22%
Return on assets
-43.3%
Return on equity
-63.1%
Return on invested capital
-42%
Return on capital employed
-31%
Return on sales
-20.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRMD stock price
How has the Repro Med Systems stock price performed over time
Intraday
-13.11%
1 week
-9.81%
1 month
-40%
1 year
34.43%
YTD
-25.97%
QTD
-25.97%
Financial performance
How have Repro Med Systems's revenue and profit performed over time
Revenue
$31.99M
Gross profit
$20.1M
Operating income
-$7.05M
Net income
-$11.97M
Gross margin
62.8%
Net margin
-37.4%
The net income has declined by 45% year-on-year
The company's operating margin rose by 40% YoY and by 5% QoQ
KRMD's operating income is up by 33% YoY
KRMD's net margin is down by 30% year-on-year but it is up by 2.1% since the previous quarter
Growth
What is Repro Med Systems's growth rate over time
Valuation
What is Repro Med Systems stock price valuation
P/E
N/A
P/B
7.37
P/S
4.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.94
KRMD's EPS is down by 47% year-on-year
KRMD's price to book (P/B) is 37% higher than its last 4 quarters average of 6.2 and 33% higher than its 5-year quarterly average of 6.4
The company's equity fell by 35% YoY and by 5% QoQ
The P/S is 30% below the 5-year quarterly average of 6.7 but 21% above the last 4 quarters average of 3.9
The revenue has grown by 12% YoY and by 3.8% from the previous quarter
Efficiency
How efficient is Repro Med Systems business performance
Repro Med Systems's ROE has plunged by 123% YoY and by 15% from the previous quarter
Repro Med Systems's return on assets has shrunk by 100% YoY and by 9% QoQ
KRMD's return on sales is up by 42% year-on-year and by 5% since the previous quarter
KRMD's return on invested capital is down by 12% since the previous quarter
Dividends
What is KRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRMD.
Financial health
How did Repro Med Systems financials performed over time
The total assets is 184% more than the total liabilities
The current ratio has contracted by 42% YoY and by 21% from the previous quarter
The quick ratio has contracted by 40% YoY and by 30% from the previous quarter
KRMD's debt is 76% smaller than its equity
The debt to equity rose by 41% YoY and by 14% QoQ
The company's equity fell by 35% YoY and by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.